Moderna Analyst: COVID-19 Vaccine Value Largely Reflected In Stock

A day ahead of an FDA panel meeting for Moderna Inc's MRNA coronavirus vaccine candidate, an analyst at Morgan Stanley stepped to the sidelines on the stock. 

The Moderna Analyst: Matthew Harrison downgraded Moderna from Outperform to Equal-weight and raised the price target from $100 to $150.

The Moderna Thesis: Moderna is likely to be a more valuable company over a multiyear period, Harrison said in a Wednesday downgrade note.

The vaccine developer is one of the most innovative and is capable of outperforming most biotech companies in the long-term, the analyst said.

The near-term stock movement is likely to be largely dictated by COVID-19 vaccine revenue realization, vaccine competition and long-term COVID-19 revenue sustainability, he said. 

Moderna's vaccine pipeline is estimated at about $100 per share, or two-thirds of its valuation, Harrison said.

The rest of the company's vaccine candidates — including those for cytomegalovirus, respiratory syncytial virus, human metapneumovirus and parainfluenza type 3 — are similar in value to the COVID-19 opportunity, the analyst said. 

Related Link: The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics

While vaccines represent the majority of Moderna's valuation, significant upside exists in both rare diseases and oncology, he said. 

"And with investor expectations closer to the bull case than the bear case on COVID-19, we think its appropriate to step to the sidelines for now and look for entry points to better realize the potential long-term value," Harrison said. 

Morgan Stanley sees COVID-19 revenue as providing the company with a war chest of $10 billion to $20 billion in cash, which the sell-side firm said could come in handy to dramatically accelerate its pipeline and provide the scale needed to realize the broad opportunity of mRNA. 

"This will further distance the company from its mRNA competition and should not be overlooked," Harrison said. 

MRNA Price Action: At last check, Moderna shares were sliding 6.25% to $138.02. 

Related Link: The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal

Posted In: CoronavirusCovid-19Matthew HarrisonMorgan StanleyvaccineAnalyst ColorBiotechDowngradesHealth CarePrice TargetAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.